Feasibility of PRIME: A Cognitive Neuroscience-Informed Mobile App Intervention to Enhance Motivated Behavior and Improve Quality of Life in Recent Onset Schizophrenia

Danielle Schlosser, Timothy Campellone, Daniel Kim, Brandy Truong, Silvia Vergani, Charlie Ward, Sophia Vinogradov, Danielle Schlosser, Timothy Campellone, Daniel Kim, Brandy Truong, Silvia Vergani, Charlie Ward, Sophia Vinogradov

Abstract

Background: Despite improvements in treating psychosis, schizophrenia remains a chronic and debilitating disorder that affects approximately 1% of the US population and costs society more than depression, dementia, and other medical illnesses across most of the lifespan. Improving functioning early in the course of illness could have significant implications for long-term outcome of individuals with schizophrenia. Yet, current gold-standard treatments do not lead to clinically meaningful improvements in outcome, partly due to the inherent challenges of treating a population with significant cognitive and motivational impairments. The rise of technology presents an opportunity to develop novel treatments that may circumvent the motivational and cognitive challenges observed in schizophrenia.

Objective: The purpose of this study was two-fold: (1) to evaluate the feasibility and acceptability of implementing a Personalized Real-Time Intervention for Motivation Enhancement (PRIME), a mobile app intervention designed to target reward-processing impairments, enhance motivation, and thereby improve quality of life in recent onset schizophrenia, and (2) evaluate the empirical benefits of using an iterative, user-centered design (UCD) process.

Methods: We conducted two design workshops with 15 key stakeholders, followed by a series of in-depth interviews in collaboration with IDEO, a design and innovation firm. The UCD approach ultimately resulted in the first iteration of PRIME, which was evaluated by 10 RO participants. Results from the Stage 1 participants were then used to guide the next iteration that is currently being evaluated in an ongoing RCT. Participants in both phases were encouraged to use the app daily with a minimum frequency of 1/week over a 12-week period.

Results: The UCD process resulted in the following feature set: (1) delivery of text message (short message service, SMS)-based motivational coaching from trained therapists, (2) individualized goal setting in prognostically important psychosocial domains, (3) social networking via direct peer-to-peer messaging, and (4) community "moments feed" to capture and reinforce rewarding experiences and goal achievements. Users preferred an experience that highlighted several of the principles of self-determination theory, including the desire for more control of their future (autonomy and competence) and an approach that helps them improve existing relationships (relatedness). IDEO, also recommended an approach that was casual, friendly, and nonstigmatizing, which is in line with the recovery model of psychosis. After 12-weeks of using PRIME, participants used the app, on average, every other day, were actively engaged with its various features each time they logged in and retention and satisfaction was high (20/20, 100% retention, high satisfaction ratings). The iterative design process lead to a 2- to 3-fold increase in engagement from Stage 1 to Stage 2 in almost each aspect of the platform.

Conclusions: These results indicate that the neuroscience-informed mobile app, PRIME, is a feasible and acceptable intervention for young people with schizophrenia.

Keywords: coaching; mobile app; motivation; negative symptoms; quality of life; schizophrenia; smartphone; social networking; technology-based intervention.

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Screenshots of the three primary features of PRIME (from left to right): Goals (goal-setting), Community (Text-based motivational coaching), and Moments (social networking and community feed).

References

    1. Harvey PD. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am J Psychiatry. 2011:1195–1201. doi: 10.1176/appi.ajp.2011.10121723.
    1. Saarni SI, Viertiö S, Perälä J, Koskinen S, Lönnqvist J, Suvisaari J. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. Br J Psychiatry. 2010;197:386–394. doi: 10.1192/bjp.bp.109.076489.
    1. Fervaha G, Foussias G, Agid O, Remington G. Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome. Schizophr Res. 2015 Aug;166:9–16. doi: 10.1016/j.schres.2015.04.040.
    1. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36:359–369. doi: 10.1093/schbul/sbn094.
    1. Barch D, Dowd EC. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull. 2010;36:919–934. doi: 10.1093/schbul/sbq068.
    1. Barch D, Treadway MT, Schoen N. Effort, anhedonia, and function in schizophrenia: reduced effort allocation predicts amotivation and functional impairment. J Abnorm Psychol. 2014;123:387–397. doi: 10.1037/a0036299.
    1. Gold J, Waltz JA, Matveeva TM, Kasanova Z, Strauss GP, Herbener ES, Collins AGE, Frank MJ. Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. Arch Gen Psychiatry. 2012;69:129–138. doi: 10.1001/archgenpsychiatry.2011.1269.
    1. Gold J, Waltz JA, Prentice KJ, Morris SE, Heerey EA. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull. 2008;34:835–847. doi: 10.1093/schbul/sbn068.
    1. Cohen A, Minor KS. Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr Bull. 2010;36:143–150. doi: 10.1093/schbul/sbn061.
    1. Kring A, Barch DM. The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs. Eur Neuropsychopharmacol. 2014;24:725–736. doi: 10.1016/j.euroneuro.2013.06.007.
    1. Oorschot M, Lataster T, Thewissen V, Lardinois M, Wichers M, van OJ, Delespaul P, Myin-Germeys I. Emotional experience in negative symptoms of schizophrenia--no evidence for a generalized hedonic deficit. Schizophr Bull. 2013;39:217–225. doi: 10.1093/schbul/sbr137.
    1. Velthorst E, Koeter M, van der Gaag M, Nieman DH, Fett AJ, Smit F, Staring ABP, Meijer C, de HL. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol Med. 2015;45:453–465. doi: 10.1017/S0033291714001147.
    1. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523–537. doi: 10.1093/schbul/sbm114.
    1. Sarkar S, Hillner K, Velligan DI. Conceptualization and treatment of negative symptoms in schizophrenia. World J Psychiatry. 2015;5:352–361. doi: 10.5498/wjp.v5.i4.352.
    1. Draper M, Stutes DS, Maples NJ, Velligan DI. Cognitive adaptation training for outpatients with schizophrenia. J Clin Psychol. 2009;65:842–853. doi: 10.1002/jclp.20612.
    1. Velligan D, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, Miller AL. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res. 2008;102:312–319. doi: 10.1016/j.schres.2008.02.005.
    1. Velligan D, Diamond PM, Mintz J, Maples N, Li X, Zeber J, Ereshefsky L, Lam YWF, Castillo D, Miller AL. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008;34:483–493. doi: 10.1093/schbul/sbm111.
    1. Velligan D, Roberts D, Mintz J, Maples N, Li X, Medellin E, Brown M. A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia. Schizophr Res. 2015;165:175–180. doi: 10.1016/j.schres.2015.04.008.
    1. Velligan D, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Prihoda TJ, Miller AL. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry. 2000;157:1317–1323. doi: 10.1176/appi.ajp.157.8.1317.
    1. Ben-Zeev D, Brenner CJ, Begale M, Duffecy J, Mohr DC, Mueser KT. Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. Schizophr Bull. 2014;40:1244–1253. doi: 10.1093/schbul/sbu033.
    1. Firth J, Torous J. Smartphone apps for schizophrenia: a systematic review. JMIR Mhealth Uhealth. 2015;3:e102. doi: 10.2196/mhealth.4930.
    1. De Vito Dabbs A, Myers BA, Mc Curry KR, Dunbar-Jacob J, Hawkins RP, Begey A, Dew MA. User-centered design and interactive health technologies for patients. Comput Inform Nurs. 2009;27:175–183. doi: 10.1097/NCN.0b013e31819f7c7c.
    1. McCurdie T, Taneva S, Casselman M, Yeung M, McDaniel C, Ho W, Cafazzo J. mHealth consumer apps: the case for user-centered design. Biomed Instrum Technol. 2012;Suppl:49–56. doi: 10.2345/0899-8205-46.s2.49.
    1. Deci E, Ryan R. Intrinsic Motivation and Self-Determination in Human Behavior. New York: Plenum; 1985.
    1. Gard D, Sanchez AH, Starr J, Cooper S, Fisher M, Rowlands A, Vinogradov S. Using self-determination theory to understand motivation deficits in schizophrenia: the 'why' of motivated behavior. Schizophr Res. 2014;156:217–222. doi: 10.1016/j.schres.2014.04.027.
    1. Vancampfort D, De Hert M, Vansteenkiste Maarten, De Herdt A, Scheewe TW, Soundy A, Stubbs B, Probst M. The importance of self-determined motivation towards physical activity in patients with schizophrenia. Psychiatry Res. 2013;210:812–818. doi: 10.1016/j.psychres.2013.10.004.
    1. Wellner LJ, Kirks DR, Merten DF, Armstrong BE. Large opaque hemithorax due to cardiomegaly and atelectasis. South Med J. 1985;78:805–809.
    1. Dauwan M, Begemann MJH, Heringa SM, Sommer IE. Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2015 doi: 10.1093/schbul/sbv164.
    1. Rosenbaum S, Tiedemann A, Sherrington C, Curtis J, Ward PB. Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75:964–974. doi: 10.4088/JCP.13r08765.
    1. Siegrist K, Millier A, Amri I, Aballéa S, Toumi M. Association between social contact frequency and negative symptoms, psychosocial functioning and quality of life in patients with schizophrenia. Psychiatry Res. 2015;230:860–866. doi: 10.1016/j.psychres.2015.11.039.
    1. Flaherty AW. Brain illness and creativity: mechanisms and treatment risks. Can J Psychiatry. 2011;56:132–143.
    1. Charzynska K, Kucharska K, Mortimer A. Does employment promote the process of recovery from schizophrenia? A review of the existing evidence. Int J Occup Med Environ Health. 2015;28:407–418. doi: 10.13075/ijomeh.1896.00341.
    1. Frese F, Knight EL, Saks E. Recovery from schizophrenia: with views of psychiatrists, psychologists, and others diagnosed with this disorder. Schizophr Bull. 2009;35:370–380. doi: 10.1093/schbul/sbn175.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis 1 Disorders, Research Version, Patient Edition. (SCID-I/P) New York State Psychiatric Institute: Biometrics Research; 2002.
    1. Kay S, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
    1. McPheeters HL. Statewide mental health outcome evaluation: a perspective of two southern states. Community Ment Health J. 1984;20:44–55.
    1. Bilker W, Brensinger C, Kurtz MM, Kohler C, Gur RC, Siegel SJ, Gur RE. Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology. 2003;28:773–777. doi: 10.1038/sj.npp.1300093.
    1. Agarwal R, Anderson C, Crowley K, Kannan P. HHSA. 0023. [2016-04-12]. Understanding Development Methods From Other Industries to Improve the Design of Consumer Health IT: Background Report. (Prepared by Westat, under Contract No .
    1. Nordentoft M, Jeppesen P, Petersen L, Bertelsen M, Thorup A. The rationale for early intervention in schizophrenia and related disorders. Early Interv Psychiatry. 2009;3 Suppl 1:S3–S7. doi: 10.1111/j.1751-7893.2009.00123.x.
    1. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry Suppl. 2005;48:S116–S119. doi: 10.1192/bjp.187.48.s116.
    1. Rotondi AJ, Anderson CM, Haas GL, Eack SM, Spring MB, Ganguli R, Newhill C, Rosenstock J. Web-based psychoeducational intervention for persons with schizophrenia and their supporters: one-year outcomes. Psychiatr Serv. 2010;61:1099–1105. doi: 10.1176/ps.2010.61.11.1099.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi